OBJECTIVE: The myeloid-related proteins 8 and 14 (MRP-8/MRP-14) and neutrophil-derived S100A12 are biomarkers of inflammation. They can be used to determine the relapse risk in patients with juvenile idiopathic arthritis (JIA) after stopping antiinflammatory treatment. In this study, we tested the performance of different enzyme-linked immunosorbent assays (ELISAs) in order to validate systems available for routine use. METHODS: MRP-8/MRP-14 and S100A12 serum concentrations of 188 JIA patients in remission were analyzed. Commercially available test systems were compared to experimental ELISAs established in house. The ability of the assays to identify JIA patients at risk for relapse was analyzed. RESULTS: For MRP-8/MRP-14, the PhiCal Calprotectin and Buhlmann MRP8/14 Calprotectin ELISAs revealed hazard ratios of 2.3 and 2.1, respectively. For S100A12, the CircuLex S100A12/EN-RAGE ELISA revealed a hazard ratio of 3.1. The commercial assays allowed a JIA relapse prediction that was at least comparable to the experimental ELISAs. CONCLUSION: For the prediction of JIA relapse after stopping medication, the biomarkers MRP-8/MRP-14 and S100A12 can be determined by using assays that are available for routine use. The tested commercial MRP-8/MRP-14 and S100A12 ELISAs showed a performance comparable to well-established experimental ELISA protocols when assay-specific cutoffs for the indication of relapse prediction are thoroughly applied.
RCT Entities:
OBJECTIVE: The myeloid-related proteins 8 and 14 (MRP-8/MRP-14) and neutrophil-derived S100A12 are biomarkers of inflammation. They can be used to determine the relapse risk in patients with juvenile idiopathic arthritis (JIA) after stopping antiinflammatory treatment. In this study, we tested the performance of different enzyme-linked immunosorbent assays (ELISAs) in order to validate systems available for routine use. METHODS:MRP-8/MRP-14 and S100A12 serum concentrations of 188 JIA patients in remission were analyzed. Commercially available test systems were compared to experimental ELISAs established in house. The ability of the assays to identify JIA patients at risk for relapse was analyzed. RESULTS: For MRP-8/MRP-14, the PhiCal Calprotectin and Buhlmann MRP8/14 Calprotectin ELISAs revealed hazard ratios of 2.3 and 2.1, respectively. For S100A12, the CircuLex S100A12/EN-RAGE ELISA revealed a hazard ratio of 3.1. The commercial assays allowed a JIA relapse prediction that was at least comparable to the experimental ELISAs. CONCLUSION: For the prediction of JIA relapse after stopping medication, the biomarkers MRP-8/MRP-14 and S100A12 can be determined by using assays that are available for routine use. The tested commercial MRP-8/MRP-14 and S100A12 ELISAs showed a performance comparable to well-established experimental ELISA protocols when assay-specific cutoffs for the indication of relapse prediction are thoroughly applied.
Authors: Faekah Gohar; Janneke Anink; Halima Moncrieffe; Lisette W A Van Suijlekom-Smit; Femke H M Prince; Marion A J van Rossum; Koert M Dolman; Esther P A H Hoppenreijs; Rebecca Ten Cate; Simona Ursu; Lucy R Wedderburn; Gerd Horneff; Michael Frosch; Dirk Foell; Dirk Holzinger Journal: J Rheumatol Date: 2018-01-15 Impact factor: 4.666
Authors: Joachim Gerss; Monika Tedy; Ariane Klein; Gerd Horneff; Maria Miranda-Garcia; Christoph Kessel; Dirk Holzinger; Valda Stanevica; Joost F Swart; David A Cabral; Hermine I Brunner; Dirk Foell Journal: Ann Rheum Dis Date: 2022-03-08 Impact factor: 27.973
Authors: Daniel B Horton; Jomaira Salas; Aleksandra Wec; Melanie Kohlheim; Pooja Kapadia; Timothy Beukelman; Alexis Boneparth; Ky Haverkamp; Melissa L Mannion; L Nandini Moorthy; Sarah Ringold; Marsha Rosenthal Journal: Arthritis Care Res (Hoboken) Date: 2021-03 Impact factor: 4.794